Tesamorelin Australia: What the Research Shows
A plain, factual look at what Tesamorelin is, how it is described to act, and where it sits under Australian regulation and anti-doping rules. General information only, not legal or medical advice.
The short answer
Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH), a class sometimes described as a growth-hormone-releasing factor analogue. In Australia it is not approved by the Therapeutic Goods Administration (TGA) and is not entered on the Australian Register of Therapeutic Goods (ARTG) for general supply. As a growth-hormone-releasing peptide it falls within prescription-only controls under the Poisons Standard. It is also prohibited at all times in sport under the World Anti-Doping Agency (WADA) rules. On this site it is offered strictly as a research-use-only compound, with no human use intended or implied.
This page is general information only and is not legal or medical advice. Regulatory and anti-doping rules change over time. Information is current as at 9 October 2026. Always confirm the present position with the TGA and other primary sources, and seek qualified advice for your own situation.
What Tesamorelin is
Tesamorelin is a peptide built on the sequence of human growth-hormone-releasing hormone. Published descriptions characterise it as a 44 amino-acid chain matching endogenous GHRH, carrying an added chemical group intended to improve its stability. Because it mirrors a naturally occurring releasing hormone rather than growth hormone itself, it is grouped with the growth-hormone-releasing factor analogues rather than with growth hormone products.
In a research setting Tesamorelin is handled as a laboratory reagent. It is not a food, supplement or consumer product, and nothing on this page should be read as a suggestion to administer it to humans or animals.
How it is commonly categorised in the literature
- A synthetic analogue of growth-hormone-releasing hormone (GHRH)
- A growth-hormone-releasing factor analogue, sometimes shortened to GRF analogue
- A peptide secretagogue, meaning a compound studied for its ability to prompt release of an endogenous hormone
How it works (mechanism)
The mechanism described in the scientific literature is indirect. Rather than supplying growth hormone, Tesamorelin is reported to bind GHRH receptors on the somatotroph cells of the anterior pituitary gland. That binding is described as prompting the pituitary to release the body's own growth hormone in a pulsatile pattern similar to normal physiology.
Downstream of growth hormone, the body produces insulin-like growth factor 1 (IGF-1), which is frequently used as a marker in studies of GHRH analogues. This is stated here only to explain the biological pathway in neutral terms. It is not a claim of any benefit, outcome or effect in people.
Tesamorelin is described in the literature as acting on pituitary GHRH receptors to stimulate release of endogenous growth hormone, rather than being administered as growth hormone itself.
Regulatory status in Australia
Tesamorelin has not been registered with the TGA and does not appear on the ARTG for general supply in Australia. It has not been through the Australian evaluation and approval process, which means there is no TGA-approved product, indication or label for it in this country.
As a growth-hormone-releasing peptide, Tesamorelin sits within the prescription-only controls that apply to this class under the Poisons Standard, the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP). Substances in the Schedule 4 Prescription Only Medicine category can lawfully be supplied for human therapeutic use only under a prescription from an authorised health practitioner. Because the by-name position for any single peptide can change, you should confirm the current scheduling directly against the Poisons Standard rather than relying on a summary.
Supplying, or holding out to supply, a prescription substance for human use without the required authorisations can breach Commonwealth and state or territory law. That is one reason the material offered here is positioned for laboratory research only.
Research compound versus approved medicine
It is worth separating two very different ideas. A research compound is a substance supplied for laboratory investigation, with no approved human indication. An approved medicine is a product that a regulator has evaluated and registered for a defined use, with a label, quality controls and a prescribing framework behind it.
Internationally, Tesamorelin is known as an approved medicine in the United States, where the Food and Drug Administration (FDA) approved it under the brand name Egrifta (later reformulated as Egrifta SV) for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The United States label expressly notes it is not indicated for weight management.
A foreign approval does not create any Australian approval, indication or therapeutic claim. The United States status is provided only as factual context. In Australia, Tesamorelin remains unapproved and the research-use-only framing applies.
What the science actually shows
Most of the published human research on Tesamorelin relates to the specific HIV-associated lipodystrophy context behind its overseas approval, where controlled trials examined changes in visceral adipose tissue over defined periods. Outside that narrow setting, much of the wider interest is exploratory, and it is honest to describe it as studied or investigated rather than proven.
For researchers, the value of a compound like this lies in the questions still open: how GHRH analogues influence the growth-hormone and IGF-1 axis, how effects differ across populations, and how safety and tolerability profiles compare. These are matters under study, not settled conclusions, and none of this is a statement about what Tesamorelin will do in any individual.
How to read claims about Tesamorelin
- Treat strong outcome claims with caution, especially any promising fat loss, muscle gain or anti-ageing effects
- Distinguish the specific approved indication overseas from broad, unproven marketing language
- Look for the population, dose and duration behind any study before drawing conclusions
- Remember that research-reagent supply carries no efficacy or safety claim of any kind
Tesamorelin and sport (WADA)
Tesamorelin is prohibited in sport. The World Anti-Doping Agency lists growth-hormone-releasing factors, including GHRH and its analogues, under section S2 of the Prohibited List, the category covering peptide hormones, growth factors, related substances and mimetics. Analogues named in this class have included sermorelin, the CJC compounds and tesamorelin.
Substances in S2 are banned at all times, meaning both in-competition and out-of-competition. Athletes subject to anti-doping rules should treat any GHRH analogue as prohibited and check the current WADA Prohibited List and their national anti-doping body before going near such compounds.
A note on personal importation
People sometimes ask about bringing unapproved medicines into Australia under the TGA Personal Importation Scheme. That scheme has strict conditions. Where a substance is prescription-only in Australia, the importer is generally expected to hold a valid Australian prescription or written authority, quantities are limited, and the goods must be for personal use only, not for supply to others or for any commercial purpose.
None of this converts a research reagent into a product for human use. The personal importation rules are summarised here only so readers understand that unapproved prescription substances are tightly controlled. For your own circumstances, rely on the TGA and qualified advice rather than this general summary.
How NovaPeptides supplies Tesamorelin
NovaPeptides offers Tesamorelin strictly as a research-use-only compound for qualified laboratory settings. It is not sold for human or veterinary use, and we make no therapeutic, efficacy or outcome claims of any kind. We do not provide human dosing information or usage protocols.
What our supply involves
- Research use only, with no medical or therapeutic claims and no human dosing guidance
- Third-party analytical testing, with a Novagen certificate of analysis (COA) available on the relevant batches
- Ships within Australia from the Gold Coast
- Enquiries handled via WhatsApp for researchers who need product or documentation details
This page is general information only and is not legal or medical advice. Tesamorelin is not TGA-approved, is not on the ARTG for general supply, sits within prescription-only controls, and is prohibited in sport. It is supplied here for laboratory research only.
Frequently asked questions
Is Tesamorelin approved by the TGA in Australia?+
No. Tesamorelin is not TGA-approved and is not on the ARTG for general supply in Australia. It has not been through the Australian registration process, so there is no approved product, indication or label for it here.
What is Tesamorelin?+
It is a synthetic analogue of growth-hormone-releasing hormone (GHRH), also described as a growth-hormone-releasing factor analogue. It is a peptide based on the GHRH sequence and is handled as a research reagent on this site.
How is Tesamorelin described to work?+
Published literature describes it binding GHRH receptors on the pituitary gland and prompting release of the body's own growth hormone, with insulin-like growth factor 1 (IGF-1) produced downstream. This is a neutral description of a pathway, not a claim of any effect in people.
What schedule does Tesamorelin fall under?+
As a growth-hormone-releasing peptide it falls within prescription-only controls, the Schedule 4 Prescription Only Medicine category of the Poisons Standard applied to this class. Because by-name positions can change, confirm the current scheduling directly against the Poisons Standard.
Is Tesamorelin banned in sport?+
Yes. WADA lists growth-hormone-releasing factors and their analogues, including tesamorelin, under section S2 of the Prohibited List, and they are prohibited at all times, both in and out of competition.
Is Tesamorelin approved anywhere overseas?+
Yes. In the United States the FDA approved it under the brand name Egrifta, later reformulated as Egrifta SV, for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. A foreign approval creates no Australian approval or therapeutic claim.
Does NovaPeptides provide dosing or usage guidance?+
No. Tesamorelin is supplied for laboratory research only. We do not provide human dosing, protocols or therapeutic claims, and it is not sold for human or veterinary use.
Questions? Talk to us.
Message us on WhatsApp and we will walk you through the kits, the COAs, reconstitution and the dose tool.
Chat with us on WhatsApp